A comprehensive review of mucinous ovarian cancer: insights into epidemiology, risk factors, histological characteristics, and clinical outcomes

Authors

  • Sumedha Gupta Department of Obstetrics and Gynaecology, VMMC and SJH, New Delhi, India
  • Dheer Singh Kalwaniya Department of General Surgery, VMMC and SJH, New Delhi, India
  • Saritha Shamsunder Department of Obstetrics and Gynaecology, VMMC and SJH, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20240158

Keywords:

MOC, Metastatic mucinous carcinoma, Genomic profile, Surgery, Chemotherapy, Targeted therapy

Abstract

Mucinous ovarian cancer (MOC) represents a rare subtype within the spectrum of epithelial ovarian carcinoma (EOC). In contrast to a uniform approach applied to all EOC subtypes, MOC stands out as a distinctive entity. A nuanced understanding of the pathological features and genomic profile of MOC holds the potential for enhancing management strategies and, consequently, prognostic outcomes. The differentiation between primary MOC and metastatic mucinous carcinoma poses a challenge but is imperative for accurate clinical decision-making. Notably, early-stage MOC exhibits a favourable prognosis, while advanced disease is characterized by a less favourable outcome. Surgical intervention assumes a pivotal role both in the early stages and metastatic scenarios. Chemotherapy is typically initiated from stage II MOC onwards, with the conventional gynaecological protocol commonly employed; however, there is also precedent for the application of gastrointestinal (GI) regimens. Given the association of MOC with diverse molecular alterations, the consideration of targeted therapy emerges as a potential therapeutic avenue for this unique disease entity. The main tool used for this literature review was PubMed. MOC stands as a distinct entity within EOC subtypes, distinguished from GI mucinous carcinoma by its unique clinical behavior, pathological features, molecular profile, prognosis, and response to standard treatment. The challenges lie in both the diagnosis and treatment of MOC, emphasizing the complexity and specialized considerations required for managing this particular subtype of OC.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304.

Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Am J Pathol. 2016;186(4):733-47.

Seidman JD, Kurman RJ, Ronnett BM. Primary and Metastatic Mucinous Adenocarcinomas in the Ovaries: Incidence in Routine Practice with a New Approach to Improve Intraoperative Diagnosis. Am J Surg Pathol. 2003;27(7):985-93.

Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480:e1-e8480.

Yoshikawa N, Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T et al. Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: Analysis in Japanese women. J Gynecol Oncol. 2014;25(2):118-23.

Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45-53.

Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ et al. The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin. Int J Gynecol Pathol. 2004;23(1):41-4.

Xu W, Rush J, Rickett K, Coward JIG. Mucinous ovarian cancer: A therapeutic review. Crit Rev Oncol Hematol. 2016;102:26-36.

Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256-66.

Gore M, Hackshaw A, Brady WE, Richard TP, Richard Z, Glenn WMC et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019;153(3):541-8.

Zaino RJ, Brady MF, Lele SM, Helen M, Benjamin G, Michael AB. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer. 2011;117(3):554-62.

Dundr P, Singh N, Nožičková B, Kristýna N, Michaela B, Ivana S. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diagn Pathol. 2021;16(1):20.

Pignata S, Ferrandina G, Scarfone G, Paolo S, Franco O, Gennaro C et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.

Pisano C, Greggi S, Tambaro R, Simona L, Francesco I, Massimo DM et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res. 2005;25(5):3501-5.

McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol. 2012;65(7):596-600.

Xu W, Rush J, Rickett K, Coward JG. Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol Hematol. 2016;102:26-36.

Kelly PJ, Archbold P, Price JH, Chris C, McCluggage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63(2):169-73.

Sorensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull. 2011;58:A4331.

Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113(3):331-4.

Cobb LP, Gershenson DM. Treatment of Rare Epithelial Ovarian Tumors. Hematol Oncol Clin N Am. 2018;32(6):1011-24.

Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256-66.

Babaier A, Ghatage P. Mucinous cancer of the ovary: overview and current status. Diagnostics. 2020;10(1):52.

Pieretti M, Hopenhayn-Rich C, Khattar NH, Yangming C, Bin H, Thomas CT. Heterogeneity of ovarian cancer: relationships among histological group, stage of dis- ease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20(1):11-23.

Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol. 2003;202(1-2):97-9.

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al. Kirsten rasmutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85(5):692-6.

Lohr M, Kloppel G, Maisonneuve P, Albert BL, Jutta L. Frequency of K-rasmutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005;7(1):17-23.

Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol. 1992;47(1):53-7.

Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer. 1997;79(8):1581-6.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-10.

Schmeler KM, Tao X, Frumovitz M, Michael TD, Charlotte CS, Anil KS et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116(6pt1):269-73.

Salgado-Ceballos I, Ríos J, Pérez-Montiel D, Lenny G, Salim BM, Rosa SH et al. Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience. Int J Surg. 2017;41:1-5.

Van Baal J, Van de Vijver KK, Coffelt SB, Van der Noort V, Van Driel WJ, Kenter GG et al. Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study. BJOG. 2017;124(3):486-94.

Hoogendam JP, Vlek CA, Witteveen PO, Rhm V, Zweemer RP. Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta-analysis. BJOG. 2017;124(3):370-8.

Muyldermans K, Moerman P, Amant F, Leunen K, Neven P, Vergote I. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer. 2013;49(7):1600-8.

Park JY, Lee SH, Kim KR, Young TK, Joo HN. Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors. J Gynecol Oncol. 2019;30(6):e95.

Lin JE, Seo S, Kushner DM, Stephen LR. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208(1):46e1-4.

Ozcan A, Töz E, Turan V, Cagdas S, Aycan K, Can A et al. Should we remove the normal- looking appendix during operations for borderline mucinous ovarian neoplasms? A retrospective study of 129 cases. Int J Surg. 2015;18:99-103.

Cheng A, Li M, Kanis MJ, Ying X, Qing Z, Baoxia C et al. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. Gynecol Oncol. 2017;144(4):215-22.

Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234-44.

Karabuk E, Kose MF, Hizli D, Tas ̧kin S, Karadag ̆ B, Turan T et al. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: A matched case-control study. J Gynecol Oncol. 2013;24(2):160-66.

McGuire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY et al. Patients with Stage Iii and Stage Iv Ovarian Cancer. N Engl J Med. 1996;334(1):1-6.

Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2000;18(1):106-15.

Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084-92.

Parmar MKB, Adams M, Balestrino M, Bertelsen K, Bonazzi C, Calvert H et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet. 2002;360(9332):505-15.

Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM et al. International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125-32.

Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M et al. Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9-3):S14-9.

Nasioudis D, Haggerty AF, Giuntoli RL, Burger RA, Morgan MA, Ko EM et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol. 2019;154(2):302-7.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E et al. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97(2):436-41.

Borner M, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;14(9):1378-82.

De Gramont AD, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-47.

National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2022). 2022.

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672-705.

Kehoe S, Hook J, Nankivell M, Gordon CJ, Henry K, Tito L et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57.

Vergote I, Tropé CG, Amant F, Gunnar BK, Tom E, Nick J et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53.

Fagotti A, Ferrandina MG, Vizzielli G, Tina P, Francesco F, Valerio G et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657-64.

Van Driel WJ, Koole SN, Sikorska K, Jules HSVL, Henk WRS, Ralph HMH et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230-40.

Iavazzo C, Spiliotis J. Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer? Arch Gynecol Obstet. 2021;303(2):597-8.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med. 2009;360(14):1408-17.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.

Downloads

Published

2024-01-29

Issue

Section

Review Articles